141 related articles for article (PubMed ID: 38353619)
1. Warrior Spirit: An Interview with Victoria Gray, Sickle Cell Pioneer.
Gray V; Thomas U; Davies K
CRISPR J; 2024 Feb; 7(1):5-11. PubMed ID: 38353619
[No Abstract] [Full Text] [Related]
2. Gene therapy for sickle cell disease.
The Lancet Haematology
Lancet Haematol; 2016 Oct; 3(10):e446. PubMed ID: 27692301
[No Abstract] [Full Text] [Related]
3. CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era.
Adashi EY; Gruppuso PA; Cohen IG
Am J Med; 2024 May; 137(5):390-392. PubMed ID: 38184185
[No Abstract] [Full Text] [Related]
4. Promising Strategies for Sickle Cell Disease and β-Thalassemia.
Abbasi J
JAMA; 2021 Jan; 325(2):121. PubMed ID: 33433564
[No Abstract] [Full Text] [Related]
5. Sickle Cell Disease Approvals Include First CRISPR Gene Editing Therapy.
Harris E
JAMA; 2024 Jan; 331(4):280. PubMed ID: 38170544
[No Abstract] [Full Text] [Related]
6. Gene therapy: Erasing sickle-cell disease.
Bourzac K
Nature; 2017 Sep; 549(7673):S28-S30. PubMed ID: 28953858
[No Abstract] [Full Text] [Related]
7. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Mehta J
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107196
[No Abstract] [Full Text] [Related]
8. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Meisel R
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107195
[No Abstract] [Full Text] [Related]
9. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. Reply.
Frangoul H; Ho TW; Corbacioglu S
N Engl J Med; 2021 Jun; 384(23):e91. PubMed ID: 34107197
[No Abstract] [Full Text] [Related]
10. Graphite Bio Pauses Lead Gene Editing Program in Sickle Cell Disease.
Philippidis A
Hum Gene Ther; 2023 Feb; 34(3-4):90-93. PubMed ID: 36794977
[No Abstract] [Full Text] [Related]
11. Stem Cell Gene Editing Improved Sickle Cell Disease Outcomes.
Harris E
JAMA; 2023 Oct; 330(13):1218. PubMed ID: 37703002
[No Abstract] [Full Text] [Related]
12. Genome Editing for Sickle Cell Disease: A Little BCL11A Goes a Long Way.
Hossain MA; Bungert J
Mol Ther; 2017 Mar; 25(3):561-562. PubMed ID: 28190778
[No Abstract] [Full Text] [Related]
13. Discontinued CRISPR gene therapy for sickle-cell disease improves symptoms.
Carvalho T
Nat Med; 2023 Nov; 29(11):2669-2670. PubMed ID: 37783810
[No Abstract] [Full Text] [Related]
14. Tweaking genes with CRISPR or viruses fixes blood disorders.
Kaiser J
Science; 2020 Dec; 370(6522):1254-1255. PubMed ID: 33303593
[No Abstract] [Full Text] [Related]
15. Welcoming the Era of Gene Editing in Medicine.
Daley GQ
N Engl J Med; 2024 May; 390(18):1642-1645. PubMed ID: 38657270
[No Abstract] [Full Text] [Related]
16. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
17. A plethora of gene therapies for hemoglobinopathies.
Dunbar CE
Nat Med; 2021 Feb; 27(2):202-204. PubMed ID: 33526930
[No Abstract] [Full Text] [Related]
18. Induction of Fetal Hemoglobin by Gene Therapy.
Walters MC
N Engl J Med; 2021 Jan; 384(3):284-285. PubMed ID: 33471981
[No Abstract] [Full Text] [Related]
19. UK first to approve CRISPR treatment for diseases: what you need to know.
Wong C
Nature; 2023 Nov; 623(7988):676-677. PubMed ID: 37974039
[No Abstract] [Full Text] [Related]
20. Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation.
Chu SH; Packer M; Rees H; Lam D; Yu Y; Marshall J; Cheng LI; Lam D; Olins J; Ran FA; Liquori A; Gantzer B; Decker J; Born D; Barrera L; Hartigan A; Gaudelli N; Ciaramella G; Slaymaker IM
CRISPR J; 2021 Apr; 4(2):169-177. PubMed ID: 33876959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
